Is a Clinical Trial Right for You? Many benefits go with participating in an ankylosing spondylitis clinical trial, but trials aren’t always a good fit for everyone. You may leave the trial, for any ...

U ntil recently, the treatments for ankylosing spondylitis — a chronic, inflammatory type of arthritis that primarily affects the spine — have lagged behind those of other forms of arthritis. Luckily, ...

Bimekizumab demonstrated safety and efficacy at 2 years among patients with nonradiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS). Bimekizumab is currently FDA approved ...

Chiropractic care for ankylosing spondylitis can pose risks. Here's what you need to know about chiropractic adjustments for this joint disease.

Ankylosing spondylitis is an inflammatory disease that, over time, can cause some of the vertebrae in your spine to fuse. This fusing makes the spine less flexible and can result in a hunched-forward ...

Ankylosing spondylitis can be a devastating disease. But the good news is that the future is brighter than ever before. Here’s why I’m so optimistic. Doctors -- including primary care physicians -- ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved once-daily oral upadacitinib for the treatment of adults with active ankylosing spondylitis ...

Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints (those between the spine and hipbone). Less commonly, AS can affect other joints such ...

Medical professional societies encourage development of treatment recommendations and/or guidelines that are based on current best evidence and represent a popular way of integrating evidence-based ...

Treatment for ankylosing spondylitis (AS) aims to achieve and maintain remission. When in remission, disease activity such as inflammation, joint stiffness, and pain is low or minimal. AS is a type of ...

For decades, ankylosing spondylitis was considered a man’s disease, but new research reveals something shocking: ankylosing spondylitis hits women differently and nearly as frequently as men, yet ...

(RTTNews) - UCB announced new long-term data from the Bimzelx (bimekizumab) Phase 2b study BE AGILE and its open-label extension. Patients with ankylosing spondylitis treated with Bimzelx, an IL-17A ...